Designing new molecules that enhance solubility, delivery or control release
While there is a significant research focus in the area of lead candidate isolation, advanced excipient design are over-looked. Currently, dry powder inhalers are formulated with lactose, while drugs in pMDIs are either solubilised in ethanol or suspended using off-the shelf excipients. The Respiratory Technology group has invested significant resources in designing new excipients that can be applied to inhalation medicines. These include solubility enhancers, particle stabilisers and controlled release agents.